INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING

INHIBITORS OF TYROSINE KINASE 2 MEDIATED SIGNALING

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. L'invention concerne des composés de form...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: LITTLE, ANDREW J, VAN EPPS, STACY A, SCHRIMPF, MICHAEL R, CHIEN, ELLEN YULIN TSAI, SCHIEDLER, DAVID A, BREINLINGER, ERIC C, WEBSTER, MATTHEW P, VARGO, THOMAS R, KATCHER, MATTHEW H, FRIEDMAN, MICHAEL M, FRANK, KRISTINE E, DUNSTAN, THERESA A, COWART, MARLON D, QIU, WEI, SCANIO, MARC J, HARDEE, DAVID J, HEROLD, J. MARTIN, ARGIRIADI, MARIA A, LIU, HUAQING
Format: Patent
Sprache:eng ; fre
Schlagworte:
CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. L'invention concerne des composés de formule (I), et des sels pharmaceutiquement acceptables de ceux-ci, dans la formule, R1, R2, R3, R4a, R4b, X1, X2, X3, X4, X5 et n sont tels que définis dans la description, des compositions pharmaceutiques les comprenant, et des procédés de préparation et d'utilisation.